Several ADCs composed of a covalent association of an anti-CD19 monoclonal Ab with chemically different payloads have shown promising results for the treatment of lymphoma both in preclinical and clinical studies (Table 2) [111–116]. The gene discussed is CD19; the disease is lymphoma.